|
|
 |
|
|
|
|
Factoid of the Day
|
Friday, April 10, 2026
|
|
The U.S. Food and Drug Administration (FDA) reported that it approved ten new drugs in the first quarter of 2026, up from seven over the same period in 2025. For comparison, the FDA approved only six new drugs in the first quarter of 2018 but reached a record 59 approvals by the end of the year.
|
|
First Trust Target Outcome ETFs®
|
| |
Upcoming Unit Investment Trusts |
Initial Offer Date |
| • |
Dow® Target 10, April 2026 |
4/10/2026 |
| • |
Dow® Target Dividend, 2nd Qtr 2026 |
4/10/2026 |
| • |
S&P Dividend Aristocrats Target 25, 2nd Qtr 2026 |
4/10/2026 |
| • |
S&P Target 24, 2nd Qtr 2026 |
4/10/2026 |
| • |
S&P Target SMid 60, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Diversified Dividend, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Dividend Blend, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Dividend Double Play, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Dividend Triple Play, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Focus Four, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Global Dividend Leaders, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target Growth, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target High Quality Dividend, 2nd Qtr 2026 |
4/10/2026 |
| • |
Target VIP, 2nd Qtr 2026 |
4/10/2026 |
| • |
Value Line® Target 25, 2nd Qtr 2026 |
4/10/2026 |
| • |
Value Line® Target Safety 30, 2nd Qtr 2026 |
4/10/2026 |
| • |
Vest Large Cap Deep Buffered 30, 54 |
4/10/2026 |
| • |
40/60 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
| • |
60/40 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
| • |
75/25 Strategic Allocation, 2nd Qtr 2026 |
4/13/2026 |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|